Zynerba Financial Statements From 2010 to 2024
| ZYNEDelisted Stock | USD 1.30 0.04 3.17% |
Check Zynerba Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zynerba main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Zynerba financial statements analysis is a perfect complement when working with Zynerba Pharmaceuticals Valuation or Volatility modules.
Zynerba |
Zynerba Pharmaceuticals Company Shares Owned By Institutions Analysis
Zynerba Pharmaceuticals' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Zynerba Pharmaceuticals Shares Owned By Institutions | 12.12 % |
Most of Zynerba Pharmaceuticals' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zynerba Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
CompetitionBased on the latest financial disclosure, 12.12% of Zynerba Pharmaceuticals are shares owned by institutions. This is 72.85% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The shares owned by institutions for all United States stocks is 69.09% higher than that of the company.
Zynerba Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Zynerba Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Zynerba Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zynerba Pharmaceuticals competition to find correlations between indicators driving Zynerba Pharmaceuticals's intrinsic value. More Info.Zynerba Pharmaceuticals is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Zynerba Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Zynerba Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Zynerba Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Zynerba Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Zynerba Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Zynerba Pharmaceuticals investors use historical funamental indicators, such as Zynerba Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Zynerba Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Zynerba Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Zynerba Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Zynerba Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Zynerba Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. Zynerba Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Zynerba Stock
If you are still planning to invest in Zynerba Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zynerba Pharmaceuticals' history and understand the potential risks before investing.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |